Samrat Pharmachem Intrinsic Value
SAMRATPH Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹112.20 | ₹89.76 - ₹134.64 | -48.0% | EPS: ₹5.10, Sector P/E: 22x |
| Book Value Method | asset | ₹480.00 | ₹432.00 - ₹528.00 | +122.4% | Book Value/Share: ₹240.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹431.60 | ₹388.44 - ₹474.76 | +100.0% | Revenue/Share: ₹966.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹166.67 | ₹150.00 - ₹183.34 | -22.8% | EBITDA: ₹5.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹407.50 | ₹326.00 - ₹489.00 | +88.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹64.74 | ₹58.27 - ₹71.21 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹79.14 | ₹71.23 - ₹87.05 | -63.3% | Revenue Growth: 6.9%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹165.95 | ₹149.35 - ₹182.55 | -23.1% | EPS: ₹5.10, BVPS: ₹240.00 |
| Dividend Yield Method | dividend | ₹64.74 | ₹58.27 - ₹71.21 | -70.0% | DPS: ₹1.00, Target Yield: 2.5% |
Want to compare with current market value? Check SAMRATPH share price latest .
Valuation Comparison Chart
SAMRATPH Intrinsic Value Analysis
What is the intrinsic value of SAMRATPH?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Samrat Pharmachem (SAMRATPH) is ₹165.95 (median value). With the current market price of ₹215.80, this represents a -23.1% variance from our estimated fair value.
The valuation range spans from ₹64.74 to ₹480.00, indicating ₹64.74 - ₹480.00.
Is SAMRATPH undervalued or overvalued?
Based on our multi-method analysis, Samrat Pharmachem (SAMRATPH) appears to be trading above calculated value by approximately 23.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.69 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 2.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.38x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Samrat Pharmachem
Additional stock information and data for SAMRATPH
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹9 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-9 Cr | ₹-11 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹18 Cr | ₹18 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹5 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |